NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors

Table 2

(a) Overall hematologic CTCAE adverse events (𝑛=44). (b) Most common nonhematologic CTCAE adverse events (𝑛=44).

(a)

Hematologic adverse events	Number of events (possibly multiple events from same participant)					Number of participants experiencing (multiple) events	Number of participants (with most severe event if there are multiple)
	Grade 1	Grade 2	Grade 3	Grade 4	Total		Grade 1	Grade 2	Grade 3	Grade 4
Lymphopenia	42	105	51	2	200	34		15	17	2
Anemia	85	61	12		158	41	13	22	6
Leukopenia; (Total WBC)	83	50	16		149	30	8	12	10
Thrombocytopenia	78	13	7	2	100	29	20	4	3	2
Neutropenia (ANC/AGC)	41	39	18	1	99	26	4	11	10	1
Total hematologic AEs	329	268	104	5	706

(b)

Nonhematologic adverse events	Number of events (possibly multiple events from same participant)					Number of participants experiencing (multiple) events	Number of participants (with most severe event if there are multiple)
	Grade 1	Grade 2	Grade 3	Grade 4	Total		Grade 1	Grade 2	Grade 3	Grade 4
Hyperglycemia	81	35	8		124	34	17	12	5
Hypoalbuminemia	53	38	2		93	29	11	16	2
Hypocalcemia	59	19	1		79	33	20	12	1
Hyponatremia	50	0	9	1	60	29	22	0	6	1
Elevated AST, SGOT	42	13	2		57	30	20	8	2
Elevated ALP, ALKP	29	22	5		56	25	10	10	5
Nausea	27	23	1		51	24	9	14	1
Fatigue	20	25	5		50	29	7	17	5
Total: most commonly occurring nonheme AEs	361	175	33	1	570		116	89	27	1
Total: nonheme AEs (overall)	751	398	85	6	1243